MAPT and Alzheimer disease: They demonstrated that higher noradrenergic turnover in concert with elevated beta-amyloid and tau pathology was related to cortical neurodegeneration in a sample of subjective cognitive decline, mild cognitive impairment (MCI), and AD patients.